Marker Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Marker Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue6.593.313.511.240.470.23
Cost of Revenue13.4710.4211.9727.7918.880.00
Gross Profit-6.88-7.11-8.451.24-18.410.23
Operating Expenses
Research & Development13.4710.4211.9727.7918.8812.76
Selling, General & Administrative4.247.4811.3412.9210.479.98
Operating Expenses4.247.4811.3439.4810.4722.74
Operating Income-11.12-14.58-19.79-39.48-28.89-22.74
Other Income/Expense
Interest Income0.440.540.250.010.150.00
Interest Expense0.000.000.000.000.000.00
Other Income/Expense0.440.00-0.23-2.410.03-0.23
Income
Income Before Tax-10.68-14.04-19.78-41.88-28.71-21.43
Income Tax Expense0.050.00-0.03-0.29-0.12-0.67
Net Income-10.73-8.24-29.93-41.88-28.71-21.43
Net Income - Continuous Operations-10.73-14.05-19.78-41.880.000.00
Net Income - Discontinued Operations0.005.81-10.150.000.000.00
EBITDA-4.53-11.79-17.00-36.32-28.40-21.14
EBIT-11.12-14.58-19.79-39.48-28.89-21.43
Depreciation & Amortization0.002.792.793.160.49-0.10
Earnings Per Share
Basic EPS-1.00-1.00-4.00-5.00-6.00-
Diluted EPS-1.00-1.00-4.00-5.00-6.00-
Basic Shares Outstanding8.988.818.357.654.7045.59
Diluted Shares Outstanding8.988.818.357.654.7045.59